SCHEMBL8535616

SCHEMBL8535616

C=CCc1cc(C=C2SC(=S)NC2=O)cc(CC=C)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAT1 P18440 4/20 0.61
MEN1 O00255 2/20 0.61
POLB P06746 2/20 0.61
MAPT P10636 2/20 0.61
KMT2A Q03164 2/20 0.61
NPC1 O15118 1/20 0.61
ALDH1A1 P00352 1/20 0.61
LMNA P02545 1/20 0.61
GAA P10253 1/20 0.61
CISD1 Q9NZ45 3/20 0.57
PTGS2 P35354 1/20 0.57
DNM1 Q05193 1/20 0.56
MYC P01106 1/20 0.54
MAX P61244 1/20 0.54
PIK3CG P48736 1/20 0.53
HPGD P15428 1/20 0.50
CA2 P00918 1/20 0.50
EPHX1 P07099 1/20 0.50
PDE4B Q07343 2/20 0.49
PTP4A3 O75365 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8535614 1.00 NAT1 (0.61) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18102939 0.94 NAT1 (0.57) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18095867 0.92 NAT1 (0.55) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18103035 0.92 NAT1 (0.55) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18102959 0.92 MEN1 (0.73) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18095864 0.92 NAT1 (0.55) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18102976 0.89 CISD1 (0.74) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18103004 0.89 CISD1 (0.74) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18102958 0.87 PTP4A3 (0.54) NAT1MEN1POLBMAPTKMT2A
SCHEMBL18103100 0.86 MYC (0.68) NAT1MEN1KMT2ANPC1CISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
US-5731336-A USING ARYL-SUBSTITUTED RHODAMINES ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
US-5691367-A ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS ELI LILLY AND COMPANY (US) 1997-11-25 US disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
US-5387690-A Method of treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1995-02-07 US disclosed
US-5356917-A Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
US-5216002-A Using benzyl substituted rhodanine derivatives as pure enantiomeric form ELI LILLY AND COMPANY (US) 1993-06-01 US disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed